ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Share price should be $5.50

<< Previous

Bullboard Posts

Next >>

Post by Gbathaton Jun 08, 2021 6:46am

315 Views

Post# 33346199

Share price should be $5.50

https://s27.q4cdn.com/906368049/files/News/2020/Zacks_SCR_Research_08242020_T.PMN_Vandermosten.pdf

$5.50 as present value share price estimated by independent analyst from Sacks Small Cap Research

The valuation method looked at market opportunity and probability of success in capturing that market opportunity to determine a present day market cap and pps.

Given bitten FDA approval, I think the probability of success for PMN is improving.

When will the market catch on?

Thanks for sharing that link to the report Mole101

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario